Cagrilintide
Cagrilintide is supplied by White Label Peptides as a lyophilised powder in multi-dose vials, for laboratory and research use, to business buyers only. It sits in our weight loss category. Every batch is verified by HPLC and ships with its own Certificate of Analysis.
| Compound | Cagrilintide |
|---|---|
| Classification | Amylin Receptor Agonist |
| Peptide type | Long-Acting Amylin Analogue |
| Molecular formula | C194H312N54O59 |
| Molecular weight | Approximately 4100 g/mol |
| Structure | Synthetic peptide analogue designed to mimic the activity of amylin, a naturally occurring hormone involved in metabolic signalling and appetite regulation. |
| Form | Lyophilised powder (vials) or ready-to-use solution (pre-filled pens) |
| Appearance | White to off-white lyophilised powder prior to reconstitution |
| Presentation | Vials: 5 mg, 10 mg. Pre-filled pens: 10 mg |
| Reconstitution | Typically reconstituted using: Bacteriostatic water - Sterile laboratory-grade water |
| Storage | Store refrigerated at 2-8°C in a cool, dry environment away from direct sunlight. Long-term storage may require freezing conditions prior to reconstitution. |
Specification data is provided for identification and procurement. It is not dosing guidance and it is not a claim of any effect.
Evidence and status
- Lab work
- Animal studies
- Human studies
- Approved label
Reviewed 2026-08-26. Regulatory status is stated for procurement and varies by market. It is not legal advice.
Research
What the published literature examined
The phase 2 dose-finding trial ran at 57 sites in ten countries, randomising 706 participants to cagrilintide 0.3 to 4.5 mg, 99 to liraglutide 3.0 mg and 101 to placebo over 26 weeks, with percentage change in body weight as the primary endpoint. A separate phase 2 trial evaluated once-weekly cagrilintide 2.4 mg co-administered with once-weekly semaglutide 2.4 mg in type 2 diabetes against an active comparator. In phase 3, REDEFINE 1 randomised adults without diabetes to 68 weeks of the combination, semaglutide alone, cagrilintide alone or placebo, and REDEFINE 2 ran the combination in adults with obesity and type 2 diabetes.
What is not established
No regulator anywhere has assessed cagrilintide, alone or in combination, for any indication, so there is no approved label, route, dose, population or regulator-reviewed long-term safety profile. Its lead development path is a two-component co-administration, so single-agent characterisation is thinner than the programme headline suggests.
What distinguishes Cagrilintide
It is not an incretin at all. It is an acylated analogue of human amylin, the pancreatic hormone co-secreted with insulin, with agonist activity at amylin receptors and at the calcitonin receptor, a target no GLP-1, GIP or glucagon agonist touches. It is also the only compound here whose lead registrational path is a fixed co-administration with another compound in the same range, which is why its phase 3 trials carry both a semaglutide arm and a cagrilintide arm alongside the combination.
Sources
- ClinicalTrials.gov. NCT03856047, phase 2 dose-finding, Novo Nordisk
- Lau DCW et al. Once-weekly cagrilintide for weight management, a dose-finding phase 2 trial
- Coadministered cagrilintide and semaglutide in adults with overweight or obesity. REDEFINE 1
- Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes. REDEFINE 2
- ClinicalTrials.gov. NCT05394519, REDEFINE 2
This page describes a compound as a material and summarises published research about it. It is for general and procurement information only. It is not medical advice, not a treatment recommendation, and not guidance on use. Supplied for laboratory and research use, not for human consumption.
Specification
About this compound
The specification below is the batch-independent data. Purity and analysis date vary by batch, so they appear on the certificate issued with your order rather than on this page.
What this compound is
Cagrilintide in supply terms
Cagrilintide has the molecular formula C194H312N54O59 and a molecular weight of approximately 4100 g/mol, making it one of the larger synthetic peptides in this catalogue. Structurally it is built as an analogue of amylin, a peptide hormone, with modifications that place it in the long-acting amylin analogue category rather than the shorter native peptide class. The classification is a chemistry-based grouping, tied to sequence homology and structural modification rather than to any claim about use. The compound ships as a lyophilised powder in multi-dose research vials, standard fill 10mg, in an injectable research format. Appearance is white to off-white prior to reconstitution, and reconstitution is typically carried out with bacteriostatic water or sterile laboratory-grade water. Storage sits within the standard cold-chain band for this catalogue: 2-8C, refrigerated, shielded from direct sunlight, with freezing conditions recommended if the vial is held for an extended period before reconstitution. As with the rest of the range, each batch is documented, and the storage window on the label reflects the conditions under which that documentation was generated, so buyers should rely on the accompanying paperwork, not general guidance, as the reference for handling.
This section describes the compound as a material. It makes no claim about any effect and is not guidance on use.
What varies by batch
The page identifies the compound. The certificate records the batch.
Purity, method, analysis date and issuing party belong on the batch record rather than in page copy.
| Send the volume you need for Cagrilintide and your delivery country. We will quote against it. | Request pricing |
Same category
Also in Weight Loss
| Compound | Identifier | Presentation |
|---|---|---|
| AOD-9604 | 221231-10-3 | Vials: 5 mg. Pre-filled pens: 5 mg |
| Retatrutide | C221H342N46O68 | Vials: 5 mg, 10 mg, 15 mg, 20 m... |
| Semaglutide | 910463-68-2 | Vials: 2 mg, 5 mg, 10 mg, 15 mg... |
| Tirzepatide | 2023788-19-2 | Vials: 5 mg, 10 mg, 15 mg, 20 m... |
Questions
Supply, answered
Is Cagrilintide available for private label?
Yes. It can be supplied under your own brand on the vial and the carton, with the Certificate of Analysis issued under your product name.
What is the minimum order quantity?
Set for this compound specifically and confirmed at the enquiry stage, before you commit.
What purity is supplied?
98 percent or higher, verified by HPLC. The certificate issued with your batch carries the actual figure for that batch.
How is it shipped?
As lyophilised powder in multi-dose vials, packed for transit. Delivery in 5 to 7 days once the batch is released.
We already buy Cagrilintide. Can you quote against our current volume?
Yes. Send the volume and the delivery country. Pricing is tiered per compound, so the quote reflects what you buy rather than a list price.
Can you supply Cagrilintide as a second source?
Yes. Terms are agreed per compound, so you can add Cagrilintide without moving anything else you buy elsewhere.
Request pricing for Cagrilintide
Indicative volume and delivery country is enough to start. We reply within one working day.